# Au Nebraska, la Cour suprême valide définitivement les lois sur le cannabis médical

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/au-nebraska-la-cour-supreme-valide-definitivement-les-lois-sur-le-cannabis-medical/
> **Published:** 2026-09-07T12:16:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:25-04:00
> **Clinical Summary:** The Nebraska Supreme Court has upheld medical cannabis laws, supporting patient access and productivity benefits.

---

✦ New

 CED Clinical Relevance
 #67
 Notable Clinical Interest
 Emerging findings or policy developments worth monitoring closely.

PolicyAnxietyPainNeurologyResearchSafetyMental Health

 Why This Matters
 This Nebraska Supreme Court validation of medical cannabis laws matters for clinicians and their patients as it could potentially expand access to medicinal cannabis, which has shown a 6.9% reduction in work absences according to a U.S. study. This development may impact clinical practice by offering an alternative treatment option for managing certain conditions, thereby possibly improving patient outcomes and work productivity.

 Clinical Summary
 

In Nebraska, the Supreme Court has definitively upheld medical cannabis laws. This legalization may have implications for patient care, as a US study suggests that medical cannabis use could potentially lead to a 6.9% reduction in work absences. Clinicians should be aware of this potential benefit and consider discussing it with patients who may benefit from medical cannabis therapy.

 Dr. Caplan’s Take
 “As a seasoned family physician specializing in cannabis medicine, the validation of Nebraska’s medical cannabis laws by the Supreme Court is a significant step forward. However, while this U.S. study indicating a 6.9% reduction in work absences is intriguing, it’s crucial to emphasize that more peer-reviewed research from human subjects is necessary before we can draw definitive clinical conclusions.”

– Dr. Benjamin Caplan, MD

 Clinical Perspective
 
 

🔬 In Nebraska, the Supreme Court has definitively upheld medical cannabis laws, marking a significant shift in policy. While this development is promising for patients seeking alternative treatments, it’s crucial to acknowledge the complexity of integrating cannabis into clinical practice.

Research suggests potential benefits, such as a 6.9% reduction in work absences associated with medical cannabis use in the U.S., but it’s essential to consider confounding factors like dosage, strain, and individual patient responses.

In practice, healthcare providers should approach medical cannabis with caution, emphasizing open dialogue about its potential benefits and risks, and encouraging patients to discuss any changes in their medication regimen. As always, evidence-based decision-making remains the cornerstone of quality care.

 

 

💬 Join the Conversation

 

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

 

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/)

Have thoughts on this? Share it:

[X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Au%20Nebraska%2C%20la%20Cour%20supr%C3%AAme%20valide%20d%C3%A9finitivement%20les%20lois%20sur%20le%20cannabis%20m%C3%A9dical%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90860)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90860)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Au%20Nebraska%2C%20la%20Cour%20supr%C3%AAme%20valide%20d%C3%A9finitivement%20les%20lois%20sur%20le%20cannabis%20m%C3%A9dical%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90860)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

📰 Source: [https://www.newsweed.fr/en/nebraska-cour-supreme-lois-cannabis-medical/](https://www.newsweed.fr/en/nebraska-cour-supreme-lois-cannabis-medical/)

 Further Reading
 CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/)
 Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/)
 CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/)

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
